|
Orthologous residues
|
|
HTRA2 (human): S212‑p, HTRA2 iso2 (human): S212‑p, HTRA2 (mouse): S212‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), OV2008 (ovarian)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, siRNA inhibition of enzyme
|
|
|
KINASE
|
Akt2 (human)
|
pharmacological inhibitor of upstream enzyme, transfection of constitutively active enzyme, siRNA inhibition of enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
siRNA
|
|
|
|
decrease
|
Akt siRNA
|
|
API-2
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, inhibited, intracellular localization
|
|
Effect of modification (process):
apoptosis, induced
|
